GlassScriptPhysician profile
Charles Colombo
NPI 1588660807
$1,279.31
in general payments reported to CMS, 2019-2025
15 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $93.77 · 2021: $119 · 2022: $203 · 2023: $248 · 2024: $131 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $252.95 | 2022-2025 | Clareon Panoptix Pro, Clareon, Rocklatan |
| Novartis Pharmaceuticals Corporation | $184.37 | 2020-2023 | |
| Allergan, INC. | $184.26 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $123.78 | 2019-2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $96.49 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $69.17 | 2023-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.28 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $62.20 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Amgen INC. | $48.45 | 2024 | Tepezza |
| Abbvie INC. | $44.55 | 2022-2023 | Alphagan P, Lumigan |
| Dompe US, INC. | $40.04 | 2022-2025 | Oxervate |
| Shire North American Group INC | $36.94 | 2019 | |
| Aerie Pharmaceuticals, INC. | $29.25 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $20.65 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Colombo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.